[1] COHEN MZ, EASLEY MK, ELLIS C, et al.Cancer pain management and the JCAHO's pain standards:an institutional challenge[J].J Pain Symptom Manage, 2003, 25(6):519. doi: 10.1016/S0885-3924(03)00068-X
[2] SVENDSEN KB, ANDERSEN SS, ARNER S, et al.Breakthrough pain in malignant and non-malignant diseases:a review of prevalence, characteristics and mechanisms[J].Eur J Pain, 2005, 9(2):195. doi: 10.1016/j.ejpain.2004.06.001
[3] GOUDAS LC, BLOCH R, GIALELI-GOUDAS M, et al.The epidemiology of cancer pain[J].Cancer Invest, 2005, 23(2):182. doi: 10.1081/CNV-50482
[4] LAURETTI GR, OLIVEIRA GM, PEREIRA NL.Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients[J].Br J Cancer, 2003, 89(11):2027. doi: 10.1038/sj.bjc.6601365
[5] GALLEGO AO, BARON MG, ARRANZ EE.Oxycodone:a pharmacological and clinical review[J].Clin Transl Oncol, 2007, 9(5):298. doi: 10.1007/s12094-007-0057-9
[6] ZHANG WZ, YU WJ, ZHAO XL, et al.Pharmacoeconomics evaluation of morphine, MS contin and oxycodone in the treatment of cancer pain[J].Asian Pac J Cancer Prev, 2014, 15(20):8797. doi: 10.7314/APJCP.2014.15.20.8797
[7] NOZAKI C, SAITOH A, KAMEI J.Characterization of the antinociceptive effects of oxycodone in diabetic mice[J].Eur J Pharmacol, 2006, 535(1):145.
[8] NOZAKI CI, KAMEI J.Involvement of mu1-opioid receptor on oxycodone-induced anti- nociception in diabetic mice[J].Eur J Pharmacol, 2007, 560(2/3):160.
[9] SUNG B, LOH HH, WEI LN.Association of kappa opioid receptor mRNA upregulation in dorsal root ganglia with mechanical allodynia in mice following nerve injury[J].Neurosci Lett, 2000, 291(3):163. doi: 10.1016/S0304-3940(00)01394-X
[10] WANG YM, LIU ZW, LIU JL, et al.Efficacy and tolerability of oxycodone in moderate-severe cancerrelated pain:a metaanalysis of randomized controlled trials[J].Exp Ther Med, 2012, 4(2):249. doi: 10.3892/etm.2012.571